Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns
Executive Summary
Economic ‘pull’ incentives that don’t require direct government spending draw support from industry and academic stakeholders.
You may also be interested in...
Antibiotic Development: HHS Not Yet Sold On ‘Pull’ Incentives
As HHS develops strategic framework to combat antibiotic resistance, post-market financial incentives may not be included, despite prominent government panels recommending the idea years ago and GAO urging the department to do so in a just-released report. Stakeholders told that GAO reimbursement reform won't be enough to spur a strong antibiotic pipeline.
US FDA Joins Chorus Of Concerns About Results Of GAIN Act
It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.
AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)
The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.